Pharmaceutical Jazz Pharmaceuticasls has announced positive top-line results from the Phase III double-blind, multicenter, placebo-controlled, randomized withdrawal study evaluating the efficacy and safety of an investigational use of Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution in adult patients with idiopathic hypersomnia. 8 October 2020